Semaglutide Dosage Chart for Research
This comprehensive dosage reference guide provides researchers with the titration schedules, concentration calculations, and dosing protocols used in major semaglutide clinical trials. These charts serve as reference materials for designing research protocols and understanding the dosing parameters that produced significant results in published studies.
Standard Research Titration Schedule
The most commonly referenced semaglutide titration schedule follows a gradual dose-escalation protocol designed to minimize gastrointestinal side effects while achieving target therapeutic concentrations:
Metabolic Research Protocol (SUSTAIN Trials)
| Week | Weekly Dose | Duration | Purpose |
|---|---|---|---|
| Weeks 1-4 | 0.25 mg | 4 weeks | Initiation phase |
| Weeks 5-8 | 0.5 mg | 4 weeks | First escalation |
| Week 9+ | 1.0 mg | Maintenance | Target dose |
Weight Management Research Protocol (STEP Trials)
| Week | Weekly Dose | Duration | Purpose |
|---|---|---|---|
| Weeks 1-4 | 0.25 mg | 4 weeks | Initiation |
| Weeks 5-8 | 0.5 mg | 4 weeks | Escalation 1 |
| Weeks 9-12 | 1.0 mg | 4 weeks | Escalation 2 |
| Weeks 13-16 | 1.7 mg | 4 weeks | Escalation 3 |
| Week 17+ | 2.4 mg | Maintenance | Target dose |
Reconstitution and Concentration Guide
When working with lyophilized research-grade semaglutide, proper reconstitution is critical for accurate dosing. Use bacteriostatic water for reconstitution.
Concentration Reference Table (5mg Vial)
| BAC Water Added | Concentration | 0.25mg Dose | 0.5mg Dose | 1.0mg Dose | 2.4mg Dose |
|---|---|---|---|---|---|
| 1.0 mL | 5.0 mg/mL | 5 units (0.05 mL) | 10 units (0.10 mL) | 20 units (0.20 mL) | 48 units (0.48 mL) |
| 2.0 mL | 2.5 mg/mL | 10 units (0.10 mL) | 20 units (0.20 mL) | 40 units (0.40 mL) | 96 units (0.96 mL) |
| 2.5 mL | 2.0 mg/mL | 12.5 units (0.125 mL) | 25 units (0.25 mL) | 50 units (0.50 mL) | N/A* |
*2.4mg dose exceeds 1mL volume at this concentration — use higher concentration for larger doses.
Concentration Reference Table (10mg Vial)
| BAC Water Added | Concentration | 0.5mg Dose | 1.0mg Dose | 2.4mg Dose |
|---|---|---|---|---|
| 2.0 mL | 5.0 mg/mL | 10 units | 20 units | 48 units |
| 3.0 mL | 3.33 mg/mL | 15 units | 30 units | 72 units |
| 5.0 mL | 2.0 mg/mL | 25 units | 50 units | N/A* |
Dosage Conversion Quick Reference
| Dose (mg) | Dose (mcg) | Dose (?g) |
|---|---|---|
| 0.25 mg | 250 mcg | 250 ?g |
| 0.5 mg | 500 mcg | 500 ?g |
| 1.0 mg | 1,000 mcg | 1,000 ?g |
| 1.7 mg | 1,700 mcg | 1,700 ?g |
| 2.4 mg | 2,400 mcg | 2,400 ?g |
Key Clinical Trial Dosing Parameters
STEP 1 Trial Parameters
- Target dose: 2.4 mg once weekly (subcutaneous)
- Titration period: 16 weeks to reach target dose
- Treatment duration: 68 weeks total
- Result: 14.9% mean body weight reduction
SUSTAIN-6 Trial Parameters
- Doses studied: 0.5 mg and 1.0 mg once weekly
- Treatment duration: 104 weeks
- Key finding: 26% reduction in MACE (major adverse cardiovascular events)
SELECT Trial Parameters
- Target dose: 2.4 mg once weekly
- Population: 17,604 participants with overweight/obesity and established CVD
- Key finding: 20% reduction in MACE
Dosing Considerations for Researchers
Subcutaneous Administration
All major semaglutide clinical trials used subcutaneous injection, typically administered in the abdomen, thigh, or upper arm. Research protocols should specify injection site rotation to minimize local tissue reactions.
Timing Considerations
- Administration day: Semaglutide is administered once weekly on the same day each week
- Time of day: No significant difference in pharmacokinetics based on time of administration
- Relationship to meals: Can be administered regardless of meals
- Half-life: Approximately 168 hours (7 days), supporting once-weekly dosing
Dose Adjustment Considerations
Research protocols may require dose adjustments based on:
- Tolerability of gastrointestinal effects (nausea is the most common dose-limiting factor)
- Research objectives (metabolic vs. weight management endpoints)
- Study duration and design
- Comparison with other GLP-1 agonists like tirzepatide or retatrutide
How to Calculate Your Research Dose
Use this formula to calculate the injection volume for any target dose:
Volume (mL) = Target Dose (mg) ÷ Concentration (mg/mL)
For example, to draw 0.5 mg from a solution reconstituted at 2.5 mg/mL:
0.5 mg ÷ 2.5 mg/mL = 0.20 mL = 20 units on an insulin syringe
For more detailed calculation methods, see our peptide dosage calculation guide and reconstitution guide.
Frequently Asked Questions
What is the standard research dose of semaglutide?
The most commonly studied maintenance doses are 1.0 mg/week (metabolic research, SUSTAIN trials) and 2.4 mg/week (weight management research, STEP trials). Both use a graduated titration starting at 0.25 mg/week.
How long does the titration period last?
The standard titration from 0.25 mg to 2.4 mg takes 16 weeks (four 4-week escalation steps). The 1.0 mg target dose requires only 8 weeks of titration.
Can the titration schedule be accelerated?
Some research protocols have used shortened titration periods, but this is associated with higher rates of gastrointestinal adverse events. The 4-week escalation intervals used in STEP trials represent the standard approach.
How many doses does a 5mg vial provide?
At the 0.25 mg initiation dose, a 5mg vial provides 20 doses (20 weeks at once weekly). At the 2.4 mg maintenance dose, a 5mg vial provides approximately 2 doses.
Related Articles
- What is Semaglutide? Complete Research Guide
- Semaglutide: Complete Research Guide
- How to Calculate Peptide Dosages
- How to Reconstitute Peptides
All products sold by Proxiva Labs are intended for research and laboratory use only. Not for human consumption.
All products are sold strictly for research purposes only. Not for human consumption.